AMICUS THERAPEUTICS, INC.
Board Member, COO, CEO
2022-08-01–present
Bradley L. Campbell
Board Member
AMICUS THERAPEUTICS, INC.
COO
AMICUS THERAPEUTICS, INC.
CEO
AMICUS THERAPEUTICS, INC.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Bradley L. Campbell
Bradley L. Campbell is recorded as Board Member, COO and CEO at AMICUS THERAPEUTICS, INC.. AMICUS THERAPEUTICS, INC. reported in an 8-K filed April 27, 2026 that Bradley L. Campbell resigned as executive officer, effective April 27, 2026. AMICUS THERAPEUTICS, INC. reported in an 8-K filed April 27, 2026 that Bradley L. Campbell resigned as director, effective April 27, 2026. AMICUS THERAPEUTICS, INC. reported in an 8-K filed August 1, 2022 that Bradley L. Campbell was appointed Chief Executive Officer, effective August 1, 2022. The proxy statement of AMICUS THERAPEUTICS, INC. reports total compensation of $8,526,943 for Bradley L. Campbell in fiscal 2024, including a base salary of $767,308. Disclosed compensation is on record for 3 fiscal years.
“In connection with the consummation of the Merger, as of the Effective Time, all executive officers of the Company immediately prior to the Effective Time (Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark and Jeffrey P. Castelli) ceased to be executive officers of the Surviving Corporation.”
“In connection with the consummation of the Merger, as of the Effective Time, each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company's board of directors.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
AMICUS THERAPEUTICS, INC.
CEO
Proxy statement
Current2022-08-01–present
-
AMICUS THERAPEUTICS, INC.
Board Member
Proxy statement
CurrentStart not stated–present
-
AMICUS THERAPEUTICS, INC.
COO
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | AMICUS THERAPEUTICS, INC. | President and Chief Executive Officer | $767,308 | $8,526,943 |
| 2023 | AMICUS THERAPEUTICS, INC. | President and Chief Executive Officer | $698,558 | $8,202,366 |
| 2022 | AMICUS THERAPEUTICS, INC. | President and Chief Executive Officer | $591,040 | $8,997,866 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.